Free Newsletter
SPOTLIGHT: New CEO to run GSK from London
Free newsletter via e-mail
Tools
When Andrew Witty (photo) takes over as CEO in May, he'll be running GlaxoSmithKline from London rather than from the U.S. HQ in Philadelphia as his predecessor Jean-Pierre Garnier did. No significant staff or resources will be relocated, and the company will continue to have a "dual headquarters" in both cities. Witty has been living in the UK as chief of the company's European operations. Report
More stories about GlaxoSmithKline
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
